✦ LIBER ✦

The conversion of hepatitis B core antigen synthesized in e coli into e antigen

✍ Scribed by Patricia Mackay; Janice Lees; Kenneth Murray

Publisher: John Wiley and Sons
Year: 1981
Tongue: English
Weight: 527 KB
Volume: 8
Category: Article
ISSN: 0146-6615
DOI: 10.1002/jmv.1890080404

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

The e antigen (HBeAg) of hepatitis B virus (HBV) is a polypeptide of 17–20,000 daltons closely associated with the core antigen (HBcAg) of Dane particles, from which it is released by a variety of disruptive procedures. HBeAg could be a unique component of HBV core particles or a derivative of HBcAg. To resolve this question immunodiffusion experiments were carried out with preparations of HBcAg synthesized in E coli carrying a recombinant plasmid from which the HBcAg, but no other HBV gene, was expressed. HBcAg was converted into HBeAg by proteolytic degradation under dissociating conditions, thus confirming at the molecular level that HBeAg is a component of HBcAg. This offers a new route to the detection of HBeAg and antibodies to the antigen.

📜 SIMILAR VOLUMES

The nature of hepatitis B e antigen

✍ Dr. Colin R. Howard; A. R. Zanetti; Arie J. Zuckerman 📂 Article 📅 1978 🏛 John Wiley and Sons 🌐 English ⚖ 432 KB

Evolution of precore/core promoter mutat

Evolution of precore/core promoter mutations in hepatitis B carriers with hepatitis B e antigen seroreversion

✍ Chun-Jen Liu; Pei-Jer Chen; Ming-Yang Lai; Prof. Jia-Horng Kao; Ding-Shinn Chen 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 154 KB 👁 1 views

## Abstract The evolution of precore stop codon mutation (A1896) and dinucleotide mutation (T1762/A1764) in the basic core promoter (BCP) of hepatitis B virus (HBV) genome during transient seroconversion and seroreversion of hepatitis B e antigen (HBeAg) remains unclarified. Five HBeAg‐positive HBV

Hepatitis B core antigen in serum during

Hepatitis B core antigen in serum during acute hepatitis B

✍ L. Chemello; P. Pontisso; E. Schiavon; V. Thiers; G. Tagariello; Dr. A. Albert 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 313 KB

Hepatitis B core antigen was measured in sera of patients with acute and chronic hepatitis B virus infection by a modified radioimmunoassay based on high molarity treatment of samples to avoid masking of antigen by homologous antibody. A good correlation between hepatitis B core antigen levels and s

The separation and analysis of hepatitis

The separation and analysis of hepatitis B e antigen

✍ C. R. Howard; A. J. Zuckerman 📂 Article 📅 1979 🏛 John Wiley and Sons 🌐 English ⚖ 673 KB

A solid-phase radioimmunoassay has been used successfully for detecting hepatitis B e antigen in fractionated hepatitis B virus-containing serum. Ammonium sulphate precipitation followed by gel filtration through a column of Sepharose CL-6B resulted in two fractions of antigen-containing material wi

The absence of hepatitis B virus DNA in

The absence of hepatitis B virus DNA in hepatitis B e antigen positive sera from chronic hepatitis B surface antigen carriers in China

✍ Janet S. Scott; Pei-En Pan; Raymond A. Pace; Theo P. Sloots; Prof. W. Graham Coo 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 413 KB 👁 2 views

## Abstract Sera from 20 Chinese patients with chronic hepatitis B were examined for hepatitis B e antigen and hepatitis B virus (HBV) DNA. There was considerable discordance with HBV DNA not being detectable in 10 out of 13 (77%) patients who were hepatitis B e antigen positive. Further testing fo

Quantitative hepatitis B surface antigen

Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir

✍ Jung Min Lee; Sang Hoon Ahn; Hyon Suk Kim; Hana Park; Hye Young Chang; Do Young 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 384 KB 👁 2 views

Quantitative hepatitis B surface antigen (qHBsAg) and quantitative hepatitis B e antigen (qHBeAg) titers are emerging as useful tools for measuring viral loads and for predicting the virological response (VR) and serological response (SR) to pegylated interferon therapy. However, the clinical utilit